Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia

Phase 1 Recruiting 48 enrolled Second Affiliated Hospital, School of Medicine, Zhejiang University

NaSingle-groupOpen-labelTreatment

Summary

This study aims to evaluate the safety and efficacy of LILRA6-directed chimeric antigen receptor T cells (LILRA6 CAR-T cells) in patients with refractory or relapsed acute myeloid leukemia(AML).

Timeline

Start: 2025-12-01
Primary completion: 2027-10-01
Completion: 2028-10-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Anti-LILRA6 CAR-T cells	Cell therapy	—	Intravenous

Clinical Study of LILRA6 CAR-T for the Treatment of R/R Acute Myeloid Leukemia

Summary

Timeline

Drugs

Indications